Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

The clinical benefits of immune checkpoint inhibitor for thymic carcinomas ∼experience of single public hospital in Japan∼.

Uchida N, Fujita K, Okamura M, Nakatani K, Mio T.

Respir Med Case Rep. 2018 Nov 13;26:39-41. doi: 10.1016/j.rmcr.2018.11.007. eCollection 2019.

2.

Septic pulmonary embolism complicated by pyogenic spondylitis and psoas abscesses in a patient with methicillin-sensitive Staphylococcus aureus bacteraemia.

Kashihara E, Fujita K, Koyama H, Mio T.

Oxf Med Case Reports. 2018 Nov 26;2018(12):omy108. doi: 10.1093/omcr/omy108. eCollection 2018 Dec.

3.

Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy: A multicenter retrospective cohort study.

Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Hata T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T.

J Thorac Oncol. 2018 Nov 20. pii: S1556-0864(18)33418-X. doi: 10.1016/j.jtho.2018.10.167. [Epub ahead of print]

PMID:
30468872
4.

Nivolumab-induced severe acute kidney injury with a long latent phase in a patient with non-small-cell lung cancer: A case report.

Uchida N, Tsuji S, Fujita K, Koizumi M, Moriyoshi K, Mio T.

Clin Case Rep. 2018 Oct 2;6(11):2185-2188. doi: 10.1002/ccr3.1848. eCollection 2018 Nov.

5.

An implicit threat: dolutegravir-induced schizophrenic brief psychotic disorder and persistent cenesthopathy.

Kanai O, Fujita K, Mio T.

AIDS. 2018 Nov 28;32(18):2853-2854. doi: 10.1097/QAD.0000000000002029. No abstract available.

PMID:
30407255
6.

Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.

Tanaka H, Sase H, Tsukaguchi T, Hasegawa M, Tanimura H, Yoshida M, Sakata K, Fujii T, Tachibana Y, Takanashi K, Higashida A, Hasegawa K, Ono Y, Oikawa N, Mio T.

Mol Cancer Ther. 2018 Dec;17(12):2519-2529. doi: 10.1158/1535-7163.MCT-17-1180. Epub 2018 Sep 21.

PMID:
30242093
7.

Association between Mycobacterium avium complex lung disease and serum vitamin D status, antimicrobial peptide levels, and bone mineral density.

Fujita K, Ito Y, Oguma T, Mio T, Niimi A, Hirai T.

Medicine (Baltimore). 2018 Sep;97(38):e12463. doi: 10.1097/MD.0000000000012463.

8.

Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.

Sase H, Nakanishi Y, Aida S, Horiguchi-Takei K, Akiyama N, Fujii T, Sakata K, Mio T, Aoki M, Ishii N.

Mol Cancer Ther. 2018 Oct;17(10):2217-2225. doi: 10.1158/1535-7163.MCT-17-1022. Epub 2018 Jul 25.

PMID:
30045926
9.

Two cases of cavitary lung cancer with concomitant chronic infectious disease.

Fujita K, Uchida N, Horimoto K, Hashimoto M, Nakatani K, Moriyoshi K, Sawai S, Mio T.

Respir Med Case Rep. 2018 May 11;24:122-124. doi: 10.1016/j.rmcr.2018.05.010. eCollection 2018.

10.

Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease.

Kanai O, Kim YH, Demura Y, Kanai M, Ito T, Fujita K, Yoshida H, Akai M, Mio T, Hirai T.

Thorac Cancer. 2018 Jul;9(7):847-855. doi: 10.1111/1759-7714.12759. Epub 2018 May 21.

11.

Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.

Fujita K, Uchida N, Kanai O, Okamura M, Nakatani K, Mio T.

Cancer Chemother Pharmacol. 2018 Jun;81(6):1105-1109. doi: 10.1007/s00280-018-3585-9. Epub 2018 Apr 19.

PMID:
29675747
12.

Cutaneous lymphangitis carcinomatosa made cervicofacial oedema intractable in a patient with superior vena cava syndrome.

Kashihara E, Kanai O, Okamura M, Mio T.

BMJ Case Rep. 2018 Apr 19;2018. pii: bcr-2018-224206. doi: 10.1136/bcr-2018-224206.

13.

Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.

Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T.

Lung Cancer. 2018 May;119:14-20. doi: 10.1016/j.lungcan.2018.02.017. Epub 2018 Mar 2.

PMID:
29656747
14.

Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab.

Uchida N, Fujita K, Nakatani K, Mio T.

Respirol Case Rep. 2017 Dec 22;6(2):e00289. doi: 10.1002/rcr2.289. eCollection 2018 Feb.

15.

Acute onset of ulcerative colitis during chemoradiotherapy for anaplastic lymphoma kinase-positive lung adenocarcinoma.

Fujita K, Mizumoto Y, Moriyoshi K, Araki N, Mio T.

Respirol Case Rep. 2017 Dec 22;6(2):e00288. doi: 10.1002/rcr2.288. eCollection 2018 Feb.

16.

Concurrence of nivolumab-induced interstitial lung disease and cancer invasion.

Kanai O, Nakatani K, Fujita K, Okamura M, Mio T.

Respirol Case Rep. 2017 Aug 11;5(6):e00257. doi: 10.1002/rcr2.257. eCollection 2017 Nov.

17.

Nasogastric tube-administered alectinib achieved long-term survival in a crizotinib-refractory nonsmall cell lung cancer patient with a poor performance status.

Kanai O, Kim YH, Nakatani K, Fujita K, Mio T.

Clin Case Rep. 2017 Apr 26;5(6):927-930. doi: 10.1002/ccr3.973. eCollection 2017 Jun.

18.

Small cell lung cancer transformation during immunotherapy with nivolumab: A case report.

Imakita T, Fujita K, Kanai O, Terashima T, Mio T.

Respir Med Case Rep. 2017 Mar 29;21:52-55. doi: 10.1016/j.rmcr.2017.03.019. eCollection 2017.

19.

Giant mature teratoma in the mediastinum presenting with rapid growth.

Fujita K, Hayashi K, Motoishi M, Sawai S, Terashima T, Mio T.

Oxf Med Case Reports. 2016 Dec 1;2016(12):omw093. doi: 10.1093/omcr/omw093. eCollection 2016 Dec.

20.

Concomitant T790M mutation and small-cell lung cancer transformation after acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor.

Fujita K, Kim YH, Yoshizawa A, Mio T, Mishima M.

Respirol Case Rep. 2016 Dec 1;5(1):e00206. doi: 10.1002/rcr2.206. eCollection 2017 Jan.

21.

Preliminary Evaluation of a Sitafloxacin-Containing Regimen for Relapsed or Refractory Pulmonary Mycobacterium avium Complex Disease.

Fujita K, Fujita M, Ito Y, Hirai T, Mio T, Watanabe K, Mishima M.

Open Forum Infect Dis. 2016 Jul 13;3(3):ofw147. eCollection 2016 Sep.

22.

Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.

Fujita K, Terashima T, Mio T.

J Thorac Oncol. 2016 Dec;11(12):2238-2240. doi: 10.1016/j.jtho.2016.07.006. Epub 2016 Jul 14.

23.

Impact of industrial structure and soil exposure on the regional variations in pulmonary nontuberculous mycobacterial disease prevalence.

Hamada S, Ito Y, Hirai T, Murase K, Tsuji T, Fujita K, Mio T, Maekawa K, Fujii T, Ono S, Nishimura T, Hayashi A, Komori T, Fujita N, Niimi A, Ichiyama S, Chin K, Mishima M.

Int J Mycobacteriol. 2016 Jun;5(2):170-6. doi: 10.1016/j.ijmyco.2016.02.006. Epub 2016 Mar 8.

24.

Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases.

Kanai O, Fujita K, Okamura M, Nakatani K, Mio T.

Ann Oncol. 2016 Jul;27(7):1354-6. doi: 10.1093/annonc/mdw148. Epub 2016 Mar 31. No abstract available.

PMID:
27037297
25.

Repetitive responses to nanoparticle albumin-bound paclitaxel and carboplatin in malignant pleural mesothelioma.

Kanai O, Fujita K, Nakatani K, Mio T.

Respirol Case Rep. 2016 Jan 14;4(1):28-31. doi: 10.1002/rcr2.145. eCollection 2016 Mar.

26.

Rapidly progressive sarcomatoid malignant mesothelioma of the pleura mimicking pulmonary empyema.

Fujita K, Kim YH, Nakatani K, Mio T.

Clin Case Rep. 2015 Oct;3(10):875-8. doi: 10.1002/ccr3.371. Epub 2015 Sep 7.

27.

Patient with lung adenocarcinoma manifesting as an unusual migratory pulmonary infiltration.

Fujita K, Shim J, Nakatani K, Mio T.

BMJ Case Rep. 2015 Jul 31;2015. pii: bcr2015211771. doi: 10.1136/bcr-2015-211771. No abstract available.

28.

Hypereosinophilic obliterative bronchiolitis clinically mimicking diffuse panbronchiolitis: four-year follow-up.

Kobayashi T, Inoue H, Mio T.

Intern Med. 2015;54(9):1091-4. doi: 10.2169/internalmedicine.54.3767. Epub 2015 May 1.

29.

The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.

Nakanishi Y, Akiyama N, Tsukaguchi T, Fujii T, Sakata K, Sase H, Isobe T, Morikami K, Shindoh H, Mio T, Ebiike H, Taka N, Aoki Y, Ishii N.

Mol Cancer Ther. 2014 Nov;13(11):2547-58. doi: 10.1158/1535-7163.MCT-14-0248. Epub 2014 Aug 28.

30.

Invasive pulmonary aspergillosis in a patient presenting with idiopathic systemic capillary leak syndrome.

Hayama M, Shime N, Mio T.

BMJ Case Rep. 2014 May 23;2014. pii: bcr2014203764. doi: 10.1136/bcr-2014-203764.

31.

Massive haemoptysis following dabigatran administration in a patient with bronchiectasis.

Hayama M, Inoue H, Wada H, Mio T.

BMJ Case Rep. 2014 Feb 19;2014. pii: bcr2013201001. doi: 10.1136/bcr-2013-201001.

32.

[A case of lung paragonimiasis superinfection with hookworm presenting difficulty in discrimination].

Minezaki S, Hirama T, Shiono A, Masumoto A, Mio T, Utsugi H, Uchida Y, Kaga A, Hagiwara K, Kanazawa M.

Kansenshogaku Zasshi. 2013 Nov;87(6):756-60. Japanese.

PMID:
24483024
33.

[Case report; a case of lung and skin nocardiosis in a non-immunocompromised patient].

Masumoto A, Hirama T, Kawana H, Kawashima A, Shiono A, Mio T, Nagata M, Hagiwara K, Kanazawa M.

Nihon Naika Gakkai Zasshi. 2013 Oct 10;102(10):2679-81. Japanese. No abstract available.

PMID:
24400549
34.

[A case of postoperative thymic carcinoma recurrence that was effectively treated with combination chemotherapy of nedaplatin and docetaxel].

Kataoka Y, Okamoto K, Kitamura T, Hayama M, Tanaka H, Kanai O, Kobayashi T, Okamura M, Inoue H, Oshio M, Motoishi M, Mio T, Sawai S, Hanaoka J.

Gan To Kagaku Ryoho. 2013 Dec;40(13):2561-3. Review. Japanese.

PMID:
24335370
35.

Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.

Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.

Cancer Sci. 2013 Oct;104(10):1346-52. doi: 10.1111/cas.12237. Epub 2013 Aug 20.

36.

Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.

Fukudo M, Ikemi Y, Togashi Y, Masago K, Kim YH, Mio T, Terada T, Teramukai S, Mishima M, Inui K, Katsura T.

Clin Pharmacokinet. 2013 Jul;52(7):593-609. doi: 10.1007/s40262-013-0058-5.

PMID:
23532985
37.

Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.

Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M.

Cancer Chemother Pharmacol. 2012 Aug;70(2):271-6. doi: 10.1007/s00280-012-1910-2. Epub 2012 Jun 30.

PMID:
22752216
38.

Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial.

Fujita S, Katakami N, Masago K, Yoshioka H, Tomii K, Kaneda T, Hirabayashi M, Kunimasa K, Morizane T, Mio T.

BMC Cancer. 2012 May 21;12:185. doi: 10.1186/1471-2407-12-185.

39.

Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.

Nagai H, Yasuda H, Hatachi Y, Xue D, Sasaki T, Yamaya M, Sakamori Y, Togashi Y, Masago K, Ito I, Kim YH, Mio T, Mishima M.

Int J Oncol. 2012 Jul;41(1):24-30. doi: 10.3892/ijo.2012.1461. Epub 2012 May 2.

PMID:
22552400
40.

A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.

Okishio K, Mio T, Kawahara M, Yoshioka H, Yanagihara K, Daimon T, Furuse K.

Jpn J Clin Oncol. 2012 May;42(5):387-93. doi: 10.1093/jjco/hys028. Epub 2012 Mar 19.

PMID:
22430871
41.

Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer.

Kim YH, Sumiyoshi S, Hashimoto S, Masago K, Togashi Y, Sakamori Y, Okuda C, Mio T, Mishima M.

Clin Lung Cancer. 2012 Sep;13(5):385-90. doi: 10.1016/j.cllc.2011.11.009. Epub 2012 Jan 28.

PMID:
22285568
42.

A phase I study of amrubicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer: Japan multinational trial organization LC0303.

Kawahara M, Kubo A, Komuta K, Fujita Y, Sasaki Y, Fukushima M, Daimon T, Furuse K, Mishima M, Mio T.

J Thorac Oncol. 2012 Dec;7(12):1845-1849. doi: 10.1097/JTO.0b013e3181e47a62.

43.

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.

Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.

Cancer Sci. 2012 Feb;103(2):342-9. doi: 10.1111/j.1349-7006.2011.02144.x. Epub 2011 Dec 13.

44.

Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.

Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Sakamori Y, Mio T, Mishima M.

Oncol Rep. 2011 Oct;26(4):795-803. doi: 10.3892/or.2011.1354. Epub 2011 Jun 17.

PMID:
21805046
45.

Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.

Masago K, Togashi Y, Fujita S, Sakamori Y, Okuda C, Kim YH, Mio T, Mishima M.

Med Oncol. 2012 Sep;29(3):1614-21. doi: 10.1007/s12032-011-0009-7. Epub 2011 Jul 21.

PMID:
21779929
46.

Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion.

Masago K, Togashi Y, Fukudo M, Terada T, Irisa K, Sakamori Y, Kim YH, Mio T, Inui K, Mishima M.

Clin Lung Cancer. 2011 Sep;12(5):307-12. doi: 10.1016/j.cllc.2011.06.004. Epub 2011 Jul 19.

PMID:
21775215
47.

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.

Togashi Y, Masago K, Fukudo M, Tsuchido Y, Okuda C, Kim YH, Ikemi Y, Sakamori Y, Mio T, Katsura T, Mishima M.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1089-92. doi: 10.1007/s00280-011-1691-z. Epub 2011 Jun 17.

48.

Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib.

Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Sakamori Y, Okuda C, Mio T, Mishima M.

Oncology. 2010;79(5-6):355-62. doi: 10.1159/000323486. Epub 2011 Mar 24.

PMID:
21430404
49.

Two cases of cancer-associated retinopathy combined with small-cell lung cancer.

Sakamori Y, Kim YH, Okuda C, Togashi Y, Kinose D, Masago K, Mio T, Uji A, Mishima M.

Jpn J Clin Oncol. 2011 May;41(5):669-73. doi: 10.1093/jjco/hyr025. Epub 2011 Mar 7.

PMID:
21385760
50.

Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.

Togashi Y, Masago K, Fujita S, Hatachi Y, Fukuhara A, Nagai H, Sakamori Y, Kim YH, Mio T, Mishima M.

Lung Cancer. 2011 Oct;74(1):98-102. doi: 10.1016/j.lungcan.2011.01.022. Epub 2011 Mar 5.

PMID:
21377230

Supplemental Content

Support Center